Physician profile
Grace Reid
NPI 1881747889
$1,984.30
in general payments reported to CMS, 2019-2025
20 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $256 · 2021: $65.50 · 2022: $149 · 2023: $253 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $269.50 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $244.00 | 2019-2023 | Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $205.02 | 2019-2023 | Trintellix |
| Alkermes, INC. | $192.61 | 2019-2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $174.75 | 2019-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $165.30 | 2019-2023 | Austedo |
| Sunovion Pharmaceuticals INC. | $156.12 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $149.40 | 2019-2022 | |
| Lundbeck LLC | $88.12 | 2019-2023 | Rexulti |
| Indivior INC. | $72.69 | 2019 | |
| Avanir Pharmaceuticals, INC. | $71.31 | 2019-2022 | |
| Bausch Health US, LLC | $41.90 | 2020-2023 | Aplenzin |
| Allergan, INC. | $28.12 | 2019 | |
| Vanda Pharmaceuticals INC. | $26.92 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.18 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $18.87 | 2023 | Loreev Xr |
| Corium, LLC | $16.68 | 2023 | Azstarys |
| Arbor Pharmaceuticals, INC. | $15.89 | 2019 | |
| Merck Sharp & Dohme LLC | $13.59 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.